Agilent Technologies Inc. has introduced the new SureDirect Blood PCR Kit for amplification of DNA directly from blood and blood derivatives, without the need for nucleic acid extraction and isolation. This kit simplifies the DNA amplification workflow and decreases turn-around time by enabling PCR (polymerase chain reaction) directly from fresh, frozen and dried blood, as well as plasma and serum from human and animal samples.
The Agilent SureDirect Blood PCR Kit includes the company's latest novel inhibitor-resistant polymerase, DMSO, and positive control template and primers, providing the ability to overcome anti-coagulant and blood PCR inhibition and allowing for robust DNA target amplification even in high blood concentrations. Consistent amplification of GC-rich DNA targets and long amplicons are also achieved, giving researchers greater flexibility in experimental design. In addition, direct PCR from blood minimizes DNA yield loss from extraction and reduces the potential for sample mix-up and other potential sources of variation.
"Agilent is pleased to offer the new SureDirect Blood PCR Kit to the international research community," said Victor Fung, senior global marketing director of the Diagnostics and Genomics Group. "We are continually working to enhance our high-performance PCR products and are excited to add this innovative technology to our genomics portfolio."
Agilent's molecular biology solutions include PCR instrumentation, high fidelity polymerases, and specialty enzymes, along with qPCR instrumentation and reagents, and market leading mutagenesis and cloning products. This new product further expands the capabilities of researchers and clinical researchers in applications which can benefit from direct DNA amplification from blood.
Company websiteAgilent Technologies